Skip to main content
. 2014 May 5;11(8):2553–2565. doi: 10.1021/mp500161z

Figure 9.

Figure 9

Dose–response curves of Taxol and Taxol–transporter conjugates against two ex vivo subtypes of ovarian carcinoma.62 The Taxol conjugates outperformed Taxol in 9 of 9 patient samples: (A) clear cell carcinoma and (B) serous papillary carcinoma. Reproduced with permission from ref (62). Copyright 2012 Elsevier.